In yesterday’s Wall Street session, Applied Therapeutics Inc. (NASDAQ:APLT) shares traded at $1.19, up 15.53% from the previous session.
3 analysts cover Applied Therapeutics Inc. (NASDAQ:APLT), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $23.00 and a low of $18.00, we find $20.50. Given the previous closing price of $1.03, this indicates a potential upside of 1890.29 percent. APLT stock price is now 36.87% away from the 50-day moving average and 1.01% away from the 200-day moving average. The market capitalization of the company currently stands at $57.19M.
The stock has received a hold rating from 0 analysts and a buy rating from 2. Brokers who have rated the stock have averaged $20.50 as their price target over the next twelve months.
With the price target reduced from $44 to $7, Barclays Downgraded its rating from Overweight to Equal Weight for Applied Therapeutics Inc. (NASDAQ: APLT). On August 27, 2021, Goldman Downgraded its previous ‘Neutral’ rating to ‘Sell’ on the stock reducing its target price from $16 to quote $10, while ‘Truist’ rates the stock as ‘Buy’.
In other news, Shendelman Shoshana, President and CEO sold 15,870 shares of the company’s stock on Jan 11. The stock was sold for $14,442 at an average price of $0.91. Upon completion of the transaction, the President and CEO now directly owns 751,625 shares in the company, valued at $0.89 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 11, Chief Medical Officer Perfetti Riccardo sold 6,053 shares of the business’s stock. A total of $5,508 was realized by selling the stock at an average price of $0.91. This leaves the insider owning 154,856 shares of the company worth $0.18 million. Insiders disposed of 300,905 shares of company stock worth roughly $0.36 million over the past 1 year. A total of 2.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in APLT stock. A new stake in Applied Therapeutics Inc. shares was purchased by PARAMETRIC PORTFOLIO ASSOCIATES LLC during the first quarter worth $32,000. PERENNIAL INVESTMENT ADVISORS, LLC invested $14,000 in shares of APLT during the first quarter. In the first quarter, MAN GROUP PLC acquired a new stake in Applied Therapeutics Inc. valued at approximately $13,000. AMALGAMATED FINANCIAL CORP. acquired a new stake in APLT for approximately $3,000. CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. purchased a new stake in APLT valued at around $1,000 in the second quarter. In total, there are 82 active investors with 57.10% ownership of the company’s stock.
On Monday morning Applied Therapeutics Inc. (NASDAQ: APLT) stock kicked off with the opening price of $1.1000. During the past 12 months, Applied Therapeutics Inc. has had a low of $0.50 and a high of $3.49. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.20, and a quick ratio of 1.20. The fifty day moving average price for APLT is $0.8695 and a two-hundred day moving average price translates $1.1781 for the stock.
The latest earnings results from Applied Therapeutics Inc. (NASDAQ: APLT) was released for Jun, 2022.
Applied Therapeutics Inc.(APLT) Company Profile
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.